AXL Kinase Becomes a Therapeutic Target in Its Own Right

Jane De Lartigue, PhD
Published: Tuesday, Mar 17, 2020
Despite being implicated across the spectrum of cancer hallmarks, aberrant AXL signaling is just starting to emerge as a distinct anticancer target, with a growing focus on specific inhibitors as well as alternative novel drug designs.


Click to Enlarge

A Unique Receptor Family

Alterations in kinase genes are among the most common oncogenic events in cancer and thus present logical drug targets; approximately a quarter of ongoing drug development efforts involve kinase inhibitors.8

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication